Last reviewed · How we verify
Peanut
At a glance
| Generic name | Peanut |
|---|---|
| Sponsor | Penn State University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Peanuts for Cardiometabolic, Brain, and Intestinal Health (NA)
- Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) (PHASE3)
- Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis (PHASE2)
- SHAPE Pilot Trial: Skin Health and Allergy Prevention Exposure (NA)
- Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis
- Association Between Body Composition and Pain in Spinal Cord Injury (NA)
- Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy (PHASE1, PHASE2)
- Choline to Improve Malnutrition and Enhance Cognition (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peanut CI brief — competitive landscape report
- Peanut updates RSS · CI watch RSS
- Penn State University portfolio CI